Evidence map›Paper›PMID 39595946›Full record

ArticleInternational journal of molecular sciences2024

Linking Antibodies Against Apolipoprotein A-1 to Metabolic Dysfunction-Associated Steatohepatitis in Mice.

Sabrina Pagano, Emmanuel Somm, Catherine Juillard, Nicolas Liaudet, Frédérique Ino, Johan Ferrari, Vincent Braunersreuther, François R Jornayvaz, Nicolas Vuilleumier

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sabrina PaganoDivision of Laboratory Medicine, Diagnostic Department, Geneva University Hospitals, 1211 Geneva, Switzerland.
Emmanuel SommService of Endocrinology, Diabetes, Nutrition and Therapeutic Patient Education, Department of Internal Medicine, Geneva University Hospitals, 1211 Geneva, Switzerland.
Catherine JuillardDepartment of Medicine, Medical Faculty, Geneva University, 1211 Geneva, Switzerland.
Nicolas LiaudetBioimaging Core Facility, Medical Faculty, University of Geneva, 1211 Geneva, Switzerland.ORCID 0000-0002-0749-5857
Frédérique InoService of Endocrinology, Diabetes, Nutrition and Therapeutic Patient Education, Department of Internal Medicine, Geneva University Hospitals, 1211 Geneva, Switzerland.
Johan FerrariDivision of Clinical Pathology, Diagnostic Department, Geneva University Hospitals, 1211 Geneva, Switzerland.
Vincent BraunersreutherDivision of Clinical Pathology, Diagnostic Department, Geneva University Hospitals, 1211 Geneva, Switzerland.
François R JornayvazService of Endocrinology, Diabetes, Nutrition and Therapeutic Patient Education, Department of Internal Medicine, Geneva University Hospitals, 1211 Geneva, Switzerland.ORCID 0000-0001-9425-3137
Nicolas VuilleumierDivision of Laboratory Medicine, Diagnostic Department, Geneva University Hospitals, 1211 Geneva, Switzerland.

Funding

Fondation Ernst et Lucie Schmidheiny F02-13024Swiss Science national 189003
6 · The paper itself

Abstract

Metabolic dysfunction-associated fatty liver disease (MASLD) is a common liver and health issue associated with heightened cardiovascular disease (CVD) risk, with Cytokeratin 18 (CK-18) as a marker of liver injury across the MASLD to cirrhosis spectrum. Autoantibodies against apolipoprotein A-1 (AAA-1s) predict increased CVD risk, promoting atherosclerosis and liver steatosis in apoE-/- mice, though their impact on liver inflammation and fibrosis remains unclear. This study examined AAA-1s' impact on low-grade inflammation, liver steatosis, and fibrosis using a MASLD mouse model exposed to AAA-1s passive immunization (PI). Ten-week-old male C57BL/6J mice under a high-fat diet underwent PI with AAA-1s or control antibodies for ten days. Compared to controls, AAA-1-immunized mice showed higher plasma CK-18 (5.3 vs. 2.1 pg/mL,

Indexed as

Apolipoprotein A-IFatty LiverMice, Inbred C57BLAnimalsAutoantibodiesDiet, High-FatDisease Models, AnimalKeratin-18LiverMaleMiceApolipoprotein A-IAutoantibodiesKeratin-18anti-apolipoprotein A1 antibodiesCDAHFD mouseCytokeratin 18inflammationMASHMASLD

Identifiers

PMID39595946
PMCPMC11594174

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.